LICENSE AGREEMENTLicense Agreement • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the 3rd day of April, 2017 (the “Effective Date”), by and between Magenta Therapeutics, Inc., a Delaware corporation with its principal place of business located at 50 Hampshire Street, 8th floor, Cambridge, MA 02139 (“LICENSEE”) and Novartis International Pharmaceutical Ltd., a for-profit corporation with its principal place of business at Lichtstrasse 35, CH-4056 Basel, Switzerland (“NOVARTIS”). LICENSEE and NOVARTIS may, from time-to-time, be individually referred to as a “Party” and collectively referred to as the “Parties”.
MASTER DEVELOPMENT AND MANUFACTURING AGREEMENTConfidential Treatment • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • New York
This Master Development and Manufacturing Agreement (including all appendices hereto, this “Agreement”) is entered into as of February 13, 2018 (the “Effective Date”) by and between Magenta Therapeutics, Inc., a Delaware corporation having offices at 50 Hampshire Street, 8th Floor, Cambridge, MA 02139 (“Magenta”), and Bachem Americas, Inc., a California corporation, having offices at 3132 Kashiwa Street, Torrance, CA 90505 (“Bachem”). Magenta and Bachem may be referred to individually as a “Party” or collectively as the “Parties.”
EXCLUSIVE RESEARCH, DEVELOPMENT OPTION AND LICENSE AGREEMENT This Agreement is entered into with effect as of the Effective Date (as defined below) by and betweenOption and License Agreement • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • New York
CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[***]”. AN UNREDACTED VERSION OF THE DOCUMENT HAS ALSO BEEN FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION AS REQUIRED BY RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
LICENSE AGREEMENTLicense Agreement • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
This License Agreement (this “Agreement”) is entered into as of this 2nd day of November, 2016 (the “Effective Date”), by and between Magenta Therapeutics, Inc., a corporation existing under the laws of the State of Delaware, having a place of business at 245 First St. 4th Floor, Cambridge MA 02142 (“Licensee”) and President and Fellows of Harvard College, an educational and charitable corporation existing under the laws and the constitution of the Commonwealth of Massachusetts, having a place of business at Richard A. and Susan F. Smith Campus Center, Suite 727, 1350 Massachusetts Avenue, Cambridge, Massachusetts 02138 (“Harvard”).
MAGENTA THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT April 21, 2017Investors’ Rights Agreement • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of April 21, 2017, by and among Magenta Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”.
BE THE MATCH BIOTHERAPIES® COLLABORATION AGREEMENTCollaboration Agreement • March 28th, 2018 • Magenta Therapeutics, Inc. • Pharmaceutical preparations • Minnesota
This Collaboration Agreement (including all attachments hereto, this “Agreement”) is entered into and made effective November 10, 2017, by and between Be The Match BioTherapies (“BTMB”), a Minnesota nonprofit corporation, having its headquarters at 500 North 5th Street, Minneapolis, MN 55401, and Magenta Therapeutics, Inc., a Delaware corporation (“Magenta”), having a principal place of business at 50 Hampshire St, Cambridge, MA 02139 (each a “Party” and collectively the “Parties”).
